JonesResearch analyst Sean Kim initiated coverage of Clearside Biomedical with a Buy rating and $6 price target. Clearside is a biopharmaceutical company with its lead asset CLS-AX in development for the treatment of wet age-related macular degeneration, the analyst tells investors in a research note. The firm says CLS-AX is a potential first-in-class and best-in-class drug-device combination. It believes wet AMD presents a potential blockbuster market opportunity for CLS-AX a six-month maintenance therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLSD:
- Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
- Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
- Clearside Biomedical Inc (CLSD) Q1 Earnings Cheat Sheet
- Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023